HIV Prevention

$10M in milestone funding to be used for HIV fusion inhibitor

Published in Health and Medicine Week, October 27th, 2003

Biosyn, Inc., announced that the International Partnership for Microbicides (IPM) has agreed to provide up to $10 million in milestone-driven funding over the next 4 years for the advancement of cyanovirin-N (CV-N), a novel fusion inhibitor in development for the prevention of transmission of HIV.

"As a leader in the development of products with global health impact in the area of HIV, Biosyn is extremely pleased to receive this funding commitment from IPM," said Anne-Marie Corner, president and CEO of Biosyn. "These funds, combined with the previously announced $10 million grant from the National Institutes of Health, will help to ensure the rapid advancement of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2003-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry